Genmab drug epcoritamab reduces lymphoma progression or death risk by 51%
Genmab and AbbVie announced that their drug epcoritamab, when added to standard treatment for newly diagnosed diffuse large B-cell lymphoma, reduced the risk of cancer worsening or death by 51% compared to standard treatment alone.